Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Seeks To End Aricept Deal With Pfizer Once Wyeth Acquired

This article was originally published in PharmAsia News

Executive Summary

Eisai is considering an end to its co-promotion deal with U.S.-based Pfizer for the Japanese drug maker's Aricept (donepezil) for treating Alzheimer's Disease. Eisai has not disclosed its plans, but Pfizer said in a regulatory filing it intended to fight Eisai's plan to take back the drug once Pfizer's purchase of fellow U.S. drug maker Wyeth is completed. Pfizer said Eisai has no legal basis for ending the partnership for co-promoting the $482 million-a-year drug. In the filing, Pfizer said Eisai indicated it had the right to end the contract. (Click here for more - a subscription may be required

You may also be interested in...



FDA’s Cannabidiol Crackdown: What Do Warning Letters Say About CBD In Cosmetics?

Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.

Acadia’s Nuplazid Shows Nearly Three-Fold Reduction In Psychosis Relapse

Data presented at the CTAD meeting for pimavanserin in dementia-related psychosis will support an sNDA filing in 2020 for an approval that could broaden the drug’s market exponentially.

Analyzing Quality Data Is Essential. Here’s What One Expert Says Your Firm Should Do To Stay In FDA’s Good Graces

Device makers should make sure they have adequate resources to analyze quality data they take in so they can prevent the recurrence of nonconforming products, processes and procedures. That’s just one nugget of advice from former FDA investigations branch director Ricki Chase, who explains why collecting and properly handling such data is critical to complying with agency expectations in this Medtech Insight Q&A interview.

UsernamePublicRestriction

Register

SC071584

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel